Title
Psychotic Experiences and Hikikomori in a Nationally Representative Sample of Adult Community Residents in Japan: A Cross-Sectional Study
Date Issued
29 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Yasuma N
Watanabe K
Nishi D.
Ishikawa H.
Tachimori H.
Takeshima T.
Umeda M.
Kawakami N.
The University of Tokyo
The University of Tokyo
The University of Tokyo
The University of Tokyo
Publisher(s)
Frontiers Media S.A.
Abstract
Psychotic experiences (PEs) may be associated with hikikomori. In the present study, we analyzed interview data from a community-based representative sample (N = 1,616) in Japan to know the association of PEs over a life time, as well as the two components, hallucinatory experiences (HEs) and delusional experiences (DEs), with lifetime experience of hikikomori (severe social withdrawal). Logistic regression analysis was used to estimate the association between any PE, any HE, and any DE; and hikikomori, adjusting for socio-demographics and other psychopathologies (mental disorder in the past 12 months or having autistic spectrum disorder trait). Any PE was significantly associated with hikikomori [odds ratio (OR) =3.44, 95% CI = 1.14–10.33] after adjustment for sociodemographic factors, although the association attenuated after adjusting for other psychopathologies. Any DE remained significantly associated with hikikomori, even after adjustment for all the covariates (OR = 10.50, 95% CI = 1.57–70.29). Any HE was not significantly associated with hikikomori. DEs may be associated with hikikomori. However, because the study sample was small and the temporal association between DEs and hikikomori was unclear, a future study is needed to examine a causal relationship between DEs and hikikomori.
Volume
11
Language
English
OCDE Knowledge area
PsicologĂ­a
Scopus EID
2-s2.0-85101043598
Source
Frontiers in Psychiatry
ISSN of the container
16640640
Sponsor(s)
The authors declare that this study received funding from the Japan Ministry of Health, Labour, and Welfare (Grant Number H25-SEISHIN-IPPAN006) and the Japan Agency for Medical Research and Development (Grant Number 15dk0310020h0003). The overall WMHS was supported by the US National Institute of Mental Health (Grant Number R01 MH070884), the MacArthur Foundation (Grant Number R13-MH066849), the Pfizer Foundation (Grant Number R01-MH069864), the US Public Health Service (Grant Number R01 DA016558), the Fogarty International Center (Grant Number R03-TW006481), and the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Shire. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Sources of information: Directorio de ProducciĂłn CientĂ­fica Scopus